EDTA-modified mesoporous silica as supra adsorbent of copper ions with novel approach as an antidote agent in copper toxicity.


Journal

International journal of nanomedicine
ISSN: 1178-2013
Titre abrégé: Int J Nanomedicine
Pays: New Zealand
ID NLM: 101263847

Informations de publication

Date de publication:
2019
Historique:
received: 08 06 2019
accepted: 15 08 2019
entrez: 3 10 2019
pubmed: 3 10 2019
medline: 16 11 2019
Statut: epublish

Résumé

Mesoporous silica (MS) have been considered as a biocompatible compound and found to have various pharmaceutical applications. Recently, novel approaches in applications of MS as antidote agents were introduced. In this study, the capacity of ethylenediaminetetraacetic acid modified mesoporous silica (MS-EDTA) was evaluated in in vitro and in vivo adsorption of copper (Cu). The MS-EDTA was characterized by fourier transform infrared (FT-IR) and X-ray diffraction, while surface area was determined by N The MS-EDTA with surface area of 352.35 was synthesized. Scanning electron microscope showed spherical particle formation with less than 500 nm in size. Transmission electron microscope images showed porous and honeycomb structure. FT-IR spectroscopy showed an appropriate formation of functional groups. Particle efficiency was investigated for Cu adsorption. MS-EDTA in both media showed a high adsorption capability for Cu (II) adsorption in pH=1.2 and pH=7.2. In addition, the study of Langmuir, Freundlich, and Redlich-Peterson adsorption models showed that copper adsorption by MS-EDTA followed the Freundlich model with multi-layer adsorption. In vivo evaluation showed that MS-EDTA could alleviate the symptoms of acute copper poisoning by lowering Cu plasma levels. Structural evaluation showed successful formation of MS-EDTA. In vitro analysis demonstrated that supreme Cu adsorption occurs in both pH conditions (7.2 and 1.2), and was especially more favorable in simulated intestinal pH (7.2). The in vivo studies in animal models with acute Cu poisoning showed that MS-EDTA could be a potent antidote agent.

Identifiants

pubmed: 31576122
doi: 10.2147/IJN.S218760
pii: 218760
pmc: PMC6769164
doi:

Substances chimiques

Antidotes 0
Biomarkers 0
Ions 0
Silicon Dioxide 7631-86-9
Copper 789U1901C5
Edetic Acid 9G34HU7RV0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

7781-7792

Informations de copyright

© 2019 Taqanaki et al.

Déclaration de conflit d'intérêts

The authors report no conflicts of interest in this work.

Références

J Control Release. 2014 Sep 28;190:3-8
pubmed: 24794901
Toxicol Lett. 2006 May 25;163(2):109-20
pubmed: 16289865
Heliyon. 2018 Nov 12;4(11):e00930
pubmed: 30456326
J Colloid Interface Sci. 2012 Nov 1;385(1):137-46
pubmed: 22874637
J Toxicol Environ Health B Crit Rev. 2016;19(3-4):129-48
pubmed: 27282429
BMC Neurol. 2017 Feb 17;17(1):34
pubmed: 28212618
ISRN Neurol. 2011;2011:464572
pubmed: 22389819
Molecules. 2018 Jan 30;23(2):
pubmed: 29385755
Adv Drug Deliv Rev. 2019 Jan 1;138:302-325
pubmed: 30639256
Nanomedicine. 2017 Feb;13(2):745-753
pubmed: 27793790
Biotechnol Adv. 2018 Jul - Aug;36(4):968-985
pubmed: 29499341
Small. 2005 Feb;1(2):172-9
pubmed: 17193427
Int J Nanomedicine. 2008;3(2):151-67
pubmed: 18686776
Expert Opin Drug Deliv. 2017 Jun;14(6):783-796
pubmed: 27575454
Chem Soc Rev. 2012 May 7;41(9):3679-98
pubmed: 22441299
Adv Drug Deliv Rev. 2002 Sep 13;54(5):631-51
pubmed: 12204596
J Pediatr Gastroenterol Nutr. 2017 Mar;64(3):e72-e73
pubmed: 25341025
Pharmaceutics. 2018 Aug 06;10(3):
pubmed: 30082647
J Pediatr Gastroenterol Nutr. 2017 Mar;64(3):436-439
pubmed: 27482767
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019 Jan;11(1):e1515
pubmed: 29566308
Curr Pharm Des. 2017;23(14):2108-2112
pubmed: 27784242
Small. 2011 Jan 17;7(2):271-80
pubmed: 21213393
Arch Toxicol Suppl. 1997;19:305-10
pubmed: 9079217
J Basic Clin Physiol Pharmacol. 2018 Dec 19;30(1):91-101
pubmed: 30205645

Auteurs

Elham Rafiee Taqanaki (ER)

Department of Medical Nanotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran.

Reza Heidari (R)

Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Mohammad Monfared (M)

Department of Medical Nanotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran.
Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.

Lobat Tayebi (L)

School of Dentistry, Marquette University, Milwaukee, WI, USA.

Amir Azadi (A)

Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Department of Pharmaceutics, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.

Fatemeh Farjadian (F)

Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Articles similaires

Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
C-Reactive Protein Humans Biomarkers Inflammation
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Classifications MeSH